Ligand validation:6B3M

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 6B3M designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6B3M_NAG_E_401	14%	31%	0.305	0.861	0.9	1.92	1	3	0	0	100%	0.9333
6B3M_NAG_G_401	11%	51%	0.306	0.819	0.83	1.08	-	1	0	1	100%	0.9333
6B3M_NAG_K_409	9%	34%	0.335	0.832	0.85	1.83	-	3	0	0	100%	0.9333
6B3M_NAG_S_409	9%	36%	0.321	0.816	1.1	1.48	1	2	0	0	100%	0.9333
6B3M_NAG_A_401	7%	14%	0.347	0.803	1.59	2.41	3	6	0	0	100%	0.9333
6B3M_NAG_G_402	5%	23%	0.349	0.767	0.92	2.41	-	5	0	0	100%	0.9333
6B3M_NAG_F_201	2%	34%	0.461	0.729	1.04	1.66	1	3	0	1	100%	0.9333
6B3M_NAG_K_401	2%	23%	0.482	0.736	1.35	1.96	3	5	0	0	100%	0.9333
6B3M_NAG_Q_401	0%	40%	0.569	0.528	0.55	1.82	-	3	1	0	93%	0.9333
4CR0_NAG_A_1165	83%	52%	0.112	0.97	0.49	1.37	-	1	0	0	100%	0.9333
4KDQ_NAG_E_502	81%	59%	0.104	0.957	0.53	1.02	-	2	2	0	100%	0.9333
4BH0_NAG_E_1320	80%	61%	0.09	0.938	0.4	1.06	-	1	0	0	100%	0.9333
4K64_NAG_A_601	70%	61%	0.125	0.942	0.51	0.97	-	1	0	0	100%	0.9333
4CQZ_NAG_A_1327	67%	57%	0.112	0.922	0.46	1.16	-	2	0	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.81	0.95	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	99%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.